About Us


TRIO is a not-for-profit, full-service oncology CRO that leverages a unique blend of academic leaders, a global network of Investigators and a passionate, experienced team to accelerate the delivery of quality oncology trials.
We’ve spent decades conducting oncology trials from inception to completion, focusing on the best research and science to guide the development of innovative and biologically sound therapies. This translational research model allows us to bring targeted concepts into clinics on the most rational development path. We find the shortest course to save lives.
TRIO is a full-service CRO that specializes in oncology. We primarily conduct phase I to phase III trials. Our services cover the entire clinical research spectrum—from study conception to design, execution, data analysis and results presentation.
Our team of world-class clinical research professionals works hard to optimize trial design and conduction, all while establishing and maintaining effective collaborations with our Sponsors and Investigators. Our Operations team has close connections with Key Opinion Leaders who are pivotal for the design and execution of clinical trials—trials that are making a difference.
We’re proud to have built a Top Tier Network comprised of 500 highly experienced, sought-after investigational sites in more than 20 countries on four continents.
Chief Executive Officer
Vice President, Project Management
Senior Director, Quality Assurance
Vice President, Medical Affairs
Corporate Development Officer
Vice President, Information Services
Vice President, Monitoring Resources
Chief Financial Officer
Vice President, Human Resources
Vice President, Strategy and Clinical Collaborations
University of California, Los Angeles, USA
TRIO Chairman & Executive Director
University Hospital of the Friedrich-Alexander, University Erlangen-Nuremberg, Germany
University of California, Los Angeles, USA
Seoul National University, South Korea
Hospital General Universitario Gregorio Marañón, Spain
National Breast Cancer Coalition, USA
Chief Executive Officer
Chief Financial Officer
TRIO Corporate Secretary and General Counsel
University of California, Los Angeles, USA
TRIO Chairman & Executive Director
Massachusetts General Hospital and Harvard Medical School, USA
St. Vincent's Hospital, Ireland
University Hospital of the Friedrich-Alexander, University Erlangen-Nuremberg, Germany
University of Padua, Italy
University of Washington, USA
Sungkyunkwan University, South Korea
Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea
National Taiwan University Hospital, Taiwan
Vall d’Hebron University Hospital, Barcelona, Spain
Hospital General Universitario Gregorio Marañón, Spain
The Cancer Center in Radom Cancer Center, Poland
National Cancer Center Hospital East, Kashiwa, Japan
National Breast Cancer Coalition, USA
The University of Texas MD Anderson Cancer Center, USA
University of California, Los Angeles, USA
TRIO GI Cancer Scientific Committee Chair
TRIO was originally established in 1997 as BCIRG (Breast Cancer International Research Group), when we immediately contributed to establish docetaxel’s role in the treatment of early breast cancer, following the results of the BCIRG-001 trial.
In 1999, BCIRG changed its name to CIRG (Cancer International Research Group), reflecting the expanded range of cancer types in our trial portfolio. In this same year, we became one of the first groups to successfully establish a pre-randomization tumor tissue acquisition and central laboratory process, whereby patients’ tumor tissues were collected and evaluated centrally for a specific biomarker prior to entry into a clinical trial.
TRIO’s novel oncology clinical trials differ from many trials in that agent selection and study design are informed by rigorous preclinical evaluation performed by the group led by our Chairman of the Board, Dr. Dennis Slamon, at the Translational Oncology Research Laboratory (TORL) in the Jonsson Comprehensive Cancer Center (JCCC) at the University of California, Los Angeles (UCLA).
To formalize our translational research model with TORL, our name was changed to Translational Research In Oncology (TRIO) in 2011. Throughout the years, we’ve contributed to drug development in oncology from First-in-human to registration trials. Among these trials, four have led to cancer drugs or regimens that have changed the practice of oncology—helping countless patients worldwide.
Docetaxel in early breast cancer
Trastuzumbab in early breast cancer
Palbociclib in advanced breast cancer
Talazoparib in germline BRCA-mutated advanced breast cancer
TRIO-US SMO is our sister site management organization (SMO) in the US. It’s comprised of independent oncology practices across the country, providing cutting-edge cancer research and care to patients in their communities.
With the TRIO-US SMO site network, we’ve established efficiencies that allow us to expedite trial activation in the US. We can guarantee enrollment of the first patient within 100 days of the protocol package.
Our not-for-profit structure allows us to focus entirely on fulfilling our mission: to serve patients’ needs by conducting clinical trials that make a difference. This model:
VALUES: Innovation, teamwork, passion, integrity
MISSION: We aspire to change the lives of cancer patients by conducting clinical trials that make a difference
VALUE PROPOSITION: We’re a full-service oncology CRO that brings a unique blend of academic leaders, a global network of Investigators, and a passionate experienced team. We’re your partner for accelerated drug development.
At TRIO, we’re committed to creating change for the better. We do our part to nurture an inclusive future for clinical research and build trust within diverse communities. We’re committed to clinical trial enrollment that reflects the racial and ethnic diversity of the countries where our clinical trials are conducted, addressing both informational and practical barriers to clinical trial participation.
Ensuring diversity in clinical trials is a matter of equity. Everyone deserves a chance to raise their hand and participate, contribute, and ultimately benefit patients in their communities.
As a focused clinical research organization, we recognize a link between our mission to support innovation in patients’ treatment and the need to have an environmental sustainability ambition in our operating model. We commit to keep this as a priority in all our activities to reduce our environmental footprint.